PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
Simeng Wang(Shenyang Pharmaceutical University), Chunfu Wu(Shenyang Pharmaceutical University)
Cited by 10
Related Papers
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
|British Journal of Cancer|2017|77